COMMUNIQUÉS West-GlobeNewswire

Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
09/11/2026
Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia Single-arm design with a 24-week run-in followed by 48 weeks of treatment; [...]
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
09/11/2026
NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of [...]
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
09/11/2026
Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C [...]
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
09/11/2026
In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of [...]
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
09/11/2026
LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% [...]
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
09/11/2026
FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of [...]
American Shared Hospital Services Announces Third Quarter 2026 Financial Results Conference Call
09/11/2026
Call Scheduled for November 12th at 12:00 PM ET SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
NovaBridge Biosciences to Participate in Upcoming Investor Conferences
09/11/2026
ROCKVILLE, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (“NovaBridge” or the “Company”) (Nasdaq: NBP) today announced that members of its leadership team will participate in two upcoming investor [...]
GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting
09/11/2026
GT Biopharma showcased new preclinical data in an oral presentation at SITC demonstrating an enhanced effect of combining GTB-5550, a B7-H3-targeted tri-specific NK cell engager (TriKE ® ), with a KRAS inhibitor (KRASi [...]
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
09/11/2026
Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar [...]
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
09/11/2026
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral [...]
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
09/11/2026
AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on [...]
Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
09/11/2026
Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically validated pathways and have potential to address the two-thirds of people who have [...]
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
09/11/2026
Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer’s data readout in March 2027 MALVERN, Pa., [...]
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
09/11/2026
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year
09/11/2026
Dividend to be Paid Consistent with the Company's Cash Dividend Policy REHOVOT, Israel and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company [...]
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
09/11/2026
Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, [...]
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
09/11/2026
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
09/11/2026
- Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial - Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO and SUZHOU, China, [...]

Pages